Human monoclonal antibody ustekinumab is a novel Crohn’s disease (CD) treatment blocking pro-inflammatory cytokines interleukin-12 and 23. The study’s objective was to assess cost-effectiveness of ustekinumab …
news, new scholarship & more from around the world